Skip to main navigation Skip to search Skip to main content

Preliminary anti-cancer photodynamic therapeutic in vitro studies with mixed-metal binuclear ruthenium(ii)-vanadium(iv) complexes

  • Alvin A. Holder
  • , Patrick Taylor
  • , Anthony R. Magnusen
  • , Erick T. Moffett
  • , Kyle Meyer
  • , Yiling Hong
  • , Stuart E. Ramsdale
  • , Michelle Gordon
  • , Javelyn Stubbs
  • , Luke A. Seymour
  • , Dhiraj Acharya
  • , Ralph T. Weber
  • , Paul F. Smith
  • , G. Charles Dismukes
  • , Ping Ji
  • , Laura Menocal
  • , Fengwei Bai
  • , Jennie L. Williams
  • , Donald M. Cropek
  • , William L. Jarrett
  • University of Southern Mississippi
  • Old Dominion University
  • University of Dayton
  • Bruker Corporation
  • Rutgers - The State University of New Jersey, New Brunswick
  • Stony Brook University
  • U.S. Army Corps of Engineers, Construction Engineering Research Laboratory

Research output: Contribution to journalArticlepeer-review

47 Scopus citations

Abstract

We report the synthesis and characterisation of mixed-metal binuclear ruthenium(ii)-vanadium(iv) complexes, which were used as potential photodynamic therapeutic agents for melanoma cell growth inhibition. The novel complexes, [Ru(pbt)2(phen2DTT)](PF6)2·1. 5H2O 1 (where phen2DTT = 1,4-bis(1,10-phenanthrolin-5- ylsulfanyl)butane-2,3-diol and pbt = 2-(2′-pyridyl)benzothiazole) and [Ru(pbt)2(tpphz)](PF6)2·3H2O 2 (where tpphz = tetrapyrido[3,2-a:2′,3′-c:3′′, 2′′-h:2′′′,3′′′-j]phenazine) were synthesised and characterised. Compound 1 was reacted with [VO(sal-l-tryp)(H2O)] (where sal-l-tryp = N-salicylidene-l- tryptophanate) to produce [Ru(pbt)2(phen2DTT)VO(sal-l- tryp)](PF6)2·5H2O 4; while [VO(sal-l-tryp)(H2O)] was reacted with compound 2 to produce [Ru(pbt)2(tpphz)VO(sal-l-tryp)](PF6)2· 6H2O 3. All complexes were characterised by elemental analysis, HRMS, ESI MS, UV-visible absorption, ESR spectroscopy, and cyclic voltammetry, where appropriate. In vitro cell toxicity studies (with the 3-(4,5-dimethylthiazol-2- yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay) via dark and light reaction conditions were carried out with sodium diaqua-4,4′, 4′′,4′′′ tetrasulfophthalocyaninecobaltate(ii) (Na4[Co(tspc)(H2O)2]), [VO(sal-l-tryp)(phen)] ·H2O, and the chloride salts of complexes 3 and 4. Such studies involved A431, human epidermoid carcinoma cells; human amelanotic malignant melanoma cells; and HFF, non-cancerous human skin fibroblast cells. Both chloride salts of complexes 3 and 4 were found to be more toxic to melanoma cells than to non-cancerous fibroblast cells, and preferentially led to apoptosis of the melanoma cells over non-cancerous skin cells. The anti-cancer property of the chloride salts of complexes 3 and 4 was further enhanced when treated cells were exposed to light, while no such effect was observed on non-cancerous skin fibroblast cells. ESR and 51V NMR spectroscopic studies were also used to assess the stability of the chloride salts of complexes 3 and 4 in aqueous media at pH 7.19. This research illustrates the potential for using mixed-metal binuclear ruthenium(ii)-vanadium(iv) complexes to fight skin cancer.

Original languageEnglish
Pages (from-to)11881-11899
Number of pages19
JournalDalton Transactions
Volume42
Issue number33
DOIs
StatePublished - 2013

Fingerprint

Dive into the research topics of 'Preliminary anti-cancer photodynamic therapeutic in vitro studies with mixed-metal binuclear ruthenium(ii)-vanadium(iv) complexes'. Together they form a unique fingerprint.

Cite this